Literature DB >> 28078432

[Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector : S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF].

U Kiltz1, R Alten2, M Fleck3, K Krüger4, B Manger5, U Müller-Ladner6, H Nüsslein7, M Reuss-Borst8, A Schwarting9, H Schulze-Koops10, A K Tausche11, J Braun12.   

Abstract

Due to the increasing prevalence of gout, particularly in old age, the disease is becoming of increasing importance in Germany. Gout is one of the most common forms of recurrent inflammatory arthritis and is induced by the deposition of monosodium urate crystals in synovial fluid and other tissues. The principal goals of therapy in chronic gout are the symptomatic treatment of the acute joint inflammation and the causal treatment of the underlying metabolic cause, the hyperuricemia. Only a consistent and permanent reduction of the serum uric acid level ultimately results in an efficient avoidance of further gout attacks and therefore the prevention of structural damage. Due to an often inadequate treatment of gout, the target of healing the disease is often not achieved. A correct and timely diagnosis and adequate assessment of comorbidities associated with gout are, however, of substantial importance for patient and physician to achieve remission of the disease. In order to create a solid basis for a timely and effective treatment of affected patients, in 2016 the German Society of Rheumatology (DGRh) initiated the development of S2e guidelines on gouty arthritis for specialists. This article summarizes these S2e guidelines on the management of gouty arthritis in the specialist sector.

Entities:  

Keywords:  Guidelines; Hyperuricemia; Inflammation; Joint; Management

Mesh:

Substances:

Year:  2017        PMID: 28078432     DOI: 10.1007/s00393-016-0249-1

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  20 in total

Review 1.  Synovial fluid analysis for crystals.

Authors:  Eliseo Pascual; Francisca Sivera; Mariano Andrés
Journal:  Curr Opin Rheumatol       Date:  2011-03       Impact factor: 5.006

2.  A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis.

Authors:  Hein J E M Janssens; Jaap Fransen; Eloy H van de Lisdonk; Piet L C M van Riel; Chris van Weel; Matthijs Janssen
Journal:  Arch Intern Med       Date:  2010-07-12

Review 3.  [Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)].

Authors:  U Kiltz; R Alten; M Fleck; K Krüger; B Manger; U Müller-Ladner; H Nüßlein; M Reuss-Borst; A Schwarting; H Schulze-Koops; A Tausche; J Braun
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

4.  2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Authors:  Dinesh Khanna; Puja P Khanna; John D Fitzgerald; Manjit K Singh; Sangmee Bae; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

5.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Authors:  Michael A Becker; H Ralph Schumacher; Robert L Wortmann; Patricia A MacDonald; Denise Eustace; William A Palo; Janet Streit; Nancy Joseph-Ridge
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

6.  Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial.

Authors:  Thomas H Taylor; John N Mecchella; Robin J Larson; Kevin D Kerin; Todd A Mackenzie
Journal:  Am J Med       Date:  2012-11       Impact factor: 4.965

7.  Comparison of drug adherence rates among patients with seven different medical conditions.

Authors:  Becky A Briesacher; Susan E Andrade; Hassan Fouayzi; K Arnold Chan
Journal:  Pharmacotherapy       Date:  2008-04       Impact factor: 4.705

Review 8.  Imaging modalities for the classification of gout: systematic literature review and meta-analysis.

Authors:  Alexis Ogdie; William J Taylor; Mark Weatherall; Jaap Fransen; Tim L Jansen; Tuhina Neogi; H Ralph Schumacher; Nicola Dalbeth
Journal:  Ann Rheum Dis       Date:  2014-06-10       Impact factor: 19.103

9.  Adherence with urate-lowering therapies for the treatment of gout.

Authors:  Leslie R Harrold; Susan E Andrade; Becky A Briesacher; Marsha A Raebel; Hassan Fouayzi; Robert A Yood; Ira S Ockene
Journal:  Arthritis Res Ther       Date:  2009-03-27       Impact factor: 5.156

10.  Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.

Authors:  L Annemans; E Spaepen; M Gaskin; M Bonnemaire; V Malier; T Gilbert; G Nuki
Journal:  Ann Rheum Dis       Date:  2007-11-02       Impact factor: 19.103

View more
  1 in total

Review 1.  [Rheumatological care in the Rheumazentrum Ruhrgebiet Rheumatism Center-a model for conurbations].

Authors:  J Braun; U Kiltz; I Andreica; B Buehring; B Guminski; U Häusler; H Kavruk; D Kiefer; R Lochowski; B Mintrop; X Baraliakos
Journal:  Z Rheumatol       Date:  2019-10       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.